Keeping in mind the end goal to treat cancer effectively, specialists require information and the needed data is about various items. That is what is lacking from today’s therapeutic research framework, as per Eric Lefkofsky, prime supporter and CEO of Tempus, a startup with the objective to build up databases and fine-tune treatment of cancer. There’s no deficiency of patient information out there, however there is an absence of sources that join both genomic data with remedial information, Mr Lefkofsky clarified in San Diego at the Fortune Brainstorm Health meeting.
“Combining of molecular information is one factor; however you additionally require clinical information. You require remedial and result reaction information,” Lefkofsky noted. That implies besides data regarding a patient’s DNA & RNA makeup, clinicians likewise ought to know which they apply and how their outcomes.
For instance, if a specialist is taking a gander at a team of cancer patients receiving Herceptin, they should know the reason it works on 40% and not 60%. Could there be anything else happening with patients not receiving help? Are they receiving other drugs or even diabetic? Those are some of the questions doctors need to clarify. The given information ought also to flow freely between clinicians and researchers among other involved specialists.
Eric Lefkofsky is the CEO and co-founder of Tempus, an innovation organization that has established an operating system to help in battling cancer. He is an establishing accomplice of Lightbank, a venture fund investment dealing with disruptive technologies. Eric is likewise the chairman and co-founder of Groupon, a world e-commerce marketplace. He also co-founded Uptake Technologies which is a key prescient analytics platform for the globe’s biggest industries; Mediaocean, a main supplier of incorporated media obtainment innovation; Echo Global Logistics, an innovation empowered logistics & transportation outsourcing company; and InnerWorkings, a worldwide supplier of promotional solutions and managed print.
In 2006 Eric Lefkofsky set up the Lefkofsky Family Foundation, which is an independent charitable establishment, together with his wife liz to develop high-effect activities that improve lives in the society served. Lefkofsky is a graduate of Michigan University and University of Michigan Law School.
Clay Siegall is the C.E.O and Chairman of Seattle Genetics. He also serves on the boards of Alder Biopharmaceuticals, Ultragenyx and Mirna Therapeutics.Clay Siegall holds a Bachelor of Science from the University of Mary, and a doctorate from George Washington University. He is currently 55 years old. Dr. Siegall worked with the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute from 1991 to 97. Before that, he had worked with National Institutes of Health from 1988 to 1991. Dr. Siegall co-founded Seattle Genetics Inc. in 1998. It is a biotechnology company. He serves both as the C.E.O and the Chairman of the Board.Seattle Genetics is a famous biotechnology company which is focused on the development and distribution of innovative therapies based on monoclonal antibody-based for cancer treatment.
The company is based in Bothell – a suburb of Seattle.Seattle Genetics is currently the industry leader in ADCs or antibody-drug conjugates, which is a new technology developed for the purpose of harnessing abilities of the antibody to target and deliver killing agents to the cancer cells directly.
ADCs seek not to harm the non-targeted cells, reducing the harmful toxic effects of the traditional chemotherapy. It also simultaneously enhances the antitumor activity.The Corporate Governance Committee of Seattle Genetics has showed full faith in the abilities of Clay Siegall. Moreover, the Nominating Committee has also stated that his qualification and experience render him as the best candidate to run the company, which he also helped to co-found.
Dr. Seigall has dedicated two decades of his life for the cause of creating novel solutions for the problem of cancer. His work is a source of optimism for all those patients who are fighting with this scourge every day. Dr. Siegall is responsible for changing the very concept of treating cancer. His company is currently engaged in carrying out research for treating patients. However, Dr. Seigall’s business acumen is also responsible for enabling these technologies to be made available to needy patients. His most important accomplishment is that he and his company have developed a way of fighting cancer without having to deal with the harsh and harmful side effects of other, more common treatments. With Dr. Clay Seigall at the helm, Seattle Genetics is on its way to change the entire perception of how critical illnesses, like cancer, should be treated.